Yuheng Zhao

Yuheng Zhao

Auto-generated profile, based on publicly available information

Yuheng Zhao

Sun Yat-sen University Cancer Center 1 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer Guangzhou, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
XHXiaohong Hong
Xiaohong Hong
QLQian Li
Qian Li
JLJunyan Li
Junyan Li
KCKailin Chen
Kailin Chen
QHQingmei He
Qingmei He
YLYingqin Li
Yingqin Li
Purpose: Cisplatin-based chemotherapy effectively improves the distant-metastasis control in nasopharyngeal carcinoma (NPC), but approximately 30% of patients develop treatment failure due to chemoresistance. However, the underlying mechanisms remain poorly understood. Experimental Design: Circular RNA (circRNA) sequencing data were used to identify metastasis-specific circRNAs and the expression of circIPO7 was validated in NPC tissues as well as NPC cell lines by qRT-PCR. The whole transcriptional profile upon circIPO7 knockdown was applied to explore the biological function and regulatory mechanism, which were further confirmed by in vitro and in vivo metastasis/chemosensitivity assays. We also evaluated the value of circIPO7 expression in predicting NPC metastasis and cisplatin chemoresistance by analyzing a cohort of 183 NPC patients. Results: In this study, circIPO7, a novel circRNA, is found to be specifically overexpressed in NPC patients with distant metastasis. Knockdown of circIPO7 in NPC cells suppresses their metastasis and increases sensitivity to cisplatin treatment in vitro and in vivo. Mechanistically, circIPO7 binds to Y-box binding protein-1 (YBX1) protein in the cytoplasm and facilitates its phosphorylation at serine 102 (p-YBX1S102) by the kinase AKT, which further promotes YBX1 nuclear translocation and activates FGFR1, TNC, and NTRK1 transcription. Clinically, higher circIPO7 expression indicates unfavorable distant metastasis-free survival in NPC patients given cisplatin-based chemotherapy. Conclusions: Altogether, this study identifies oncogenic circIPO7 as a prognostic marker after cisplatin-based chemotherapy and as a potential therapeutic target for overcoming metastasis and chemoresistance in NPC.

22 January 2026 in Cancer Research
Verified
Journal Article
Closed access
YZYuheng Zhao
Yuheng Zhao
COChunxian Ou
Chunxian Ou
HHHuimin Huang
Huimin Huang
YWYujue Wang
Yujue Wang
JSJiaxi Shen
Jiaxi Shen
YLYingqin Li
Yingqin Li
Metabolic reprogramming under therapeutic stress may represent a targetable vulnerability for cancer treatment. Elucidation of the metabolic alterations linked to chemotherapy in nasopharyngeal carcinoma (NPC) could uncover potential therapeutic strategies. Using proteomics and transcriptomic profiles, we identified wild-type (WT) isocitrate dehydrogenase 1 (IDH1) as a crucial metabolic enzyme upregulated in gemcitabine plus cisplatin (GP) chemotherapy–resistant NPC. IDH1 reprogrammed nucleotide metabolism in response to chemotherapy, linking DNA damage repair (DDR) to ferroptosis resistance via dihydroorotate dehydrogenase (DHODH), thereby contributing to chemoresistance in NPC. Mechanistically, α-ketoglutarate (αKG), a metabolite of IDH1, enhanced chromatin accessibility to promote DHODH transcription via αKG-dependent dioxygenase AlkB homolog 5 (ALKBH5)–recruited heterogeneous nuclear ribonucleoprotein C (HNRNPC). The DHODH inhibitor BAY2402234 markedly sensitized NPC cells to chemotherapy. Clinically, a prognostic model based on DDR and ferroptosis signatures effectively predicted disease relapse risk following chemotherapy in NPC. This study links DDR to ferroptosis defense via the IDH1/αKG/ALKBH5/DHODH axis, suggesting DHODH inhibition as a promising therapeutic strategy to overcome chemoresistance in tumors harboring WT IDH1. Significance: DHODH-mediated nucleotide metabolic reprogramming represents a targetable vulnerability to counteract chemoresistance in nasopharyngeal carcinoma with wild-type IDH1 overexpression.

25 November 2025
Verified
Other
Open access
XHXiaohong Hong
Xiaohong Hong
QLQian Li
Qian Li
JLJunyan Li
Junyan Li
KCKailin Chen
Kailin Chen
QHQingmei He
Qingmei He
YLYingqin Li
Yingqin Li
Purpose:Cisplatin-based chemotherapy effectively improves the distant-metastasis control in nasopharyngeal carcinoma (NPC), but approximately 30% of patients develop treatment failure due to chemoresistance. However, the underlying mechanisms remain poorly understood.Experimental Design:Circular RNA (circRNA) sequencing data were used to identify metastasis-specific circRNAs and the expression of circIPO7 was validated in NPC tissues as well as NPC cell lines by qRT-PCR. The whole transcriptional profile upon circIPO7 knockdown was applied to explore the biological function and regulatory mechanism, which were further confirmed by in vitro and in vivo metastasis/chemosensitivity assays. We also evaluated the value of circIPO7 expression in predicting NPC metastasis and cisplatin chemoresistance by analyzing a cohort of 183 NPC patients.Results:In this study, circIPO7, a novel circRNA, is found to be specifically overexpressed in NPC patients with distant metastasis. Knockdown of circIPO7 in NPC cells suppresses their metastasis and increases sensitivity to cisplatin treatment in vitro and in vivo. Mechanistically, circIPO7 binds to Y-box binding protein-1 (YBX1) protein in the cytoplasm and facilitates its phosphorylation at serine 102 (p-YBX1S102) by the kinase AKT, which further promotes YBX1 nuclear translocation and activates FGFR1, TNC, and NTRK1 transcription. Clinically, higher circIPO7 expression indicates unfavorable distant metastasis-free survival in NPC patients given cisplatin-based chemotherapy.Conclusions:Altogether, this study identifies oncogenic circIPO7 as a prognostic marker after cisplatin-based chemotherapy and as a potential therapeutic target for overcoming metastasis and chemoresistance in NPC.

25 November 2025
Verified
Other
Open access
PDF file
XHXiaohong Hong
Xiaohong Hong
QLQian Li
Qian Li
JLJunyan Li
Junyan Li
KCKailin Chen
Kailin Chen
QHQingmei He
Qingmei He
YLYingqin Li
Yingqin Li
Supplementary Figure from CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization

17 June 2026
Verified
Other
Open access
YZYuheng Zhao
Yuheng Zhao
COChunxian Ou
Chunxian Ou
HHHuimin Huang
Huimin Huang
YWYujue Wang
Yujue Wang
JSJiaxi Shen
Jiaxi Shen
YLYingqin Li
Yingqin Li
Supplementary Figure S9. DHODH inhibition enhances GP-induced ferroptosis and antitumor efficacy with systemic safety maintained in NPC cells and xenograft models.

17 June 2026
Verified
Other
Open access
YZYuheng Zhao
Yuheng Zhao
COChunxian Ou
Chunxian Ou
HHHuimin Huang
Huimin Huang
YWYujue Wang
Yujue Wang
JSJiaxi Shen
Jiaxi Shen
YLYingqin Li
Yingqin Li
Supplementary Figure S5. IDH1-mediated αKG regulates DHODH expression through ALKBH5.